Affiliation:
1. Institut für Mikrobiologie, Zentrum für Infektionsmedizin, Stiftung Tierärztliche Hochschule Hannover, D-30173 Hannover, Germany
2. Institut für Pathologie, Stiftung Tierärztliche Hochschule Hannover, D-30173 Hannover, Germany
3. Klinik für Kleine Klauentiere und Forensische Medizin und Ambulatorische Klinik, Stiftung Tierärztliche Hochschule Hannover, D-30173 Hannover, Germany
Abstract
ABSTRACT
Streptococcus suis
causes numerous diseases in pigs, most importantly, meningitis, arthritis, septicemia, and bronchopneumonia. One of the major problems in modern swine production is the lack of a vaccine protecting against more than one
S. suis
serotype. The objective of this study was to determine the protective efficacy of a serotype 2 murein-associated protein (MAP) fraction subunit vaccine in comparison to that of a bacterin against experimental challenge with serotype 2 (containing muramidase-released protein [MRP], extracellular factor, and suilysin [SLY]) and serotype 9 (containing MRP variant MRP* and SLY) strains. MAP was shown to include different surface-associated proteins, such as the MRP and surface antigen one (SAO) expressed by both pathotypes used for challenge. The results of this study demonstrated that the serotype 2 bacterin induced protective immunity against homologous challenge. In contrast, the protective efficacy of the MAP subunit vaccine was low, though MAP immunization resulted in high serum immunoglobulin G2 titers against MRP and SAO. Importantly, immunization with bacterin but not with MAP induced opsonizing antibody titers against the serotype 2 strain, and these antibody titers were found to correlate with protection. However, after absorption with a nonencapsulated isogenic mutant, the sera from bacterin-immunized piglets failed to facilitate neutrophil killing, indicating that antibodies directed against capsule may not have been essential for opsonophagocytosis. Furthermore, induction of opsonizing antibodies against serotype 9 was not detectable in the group receiving bacterin or in the group receiving the MAP vaccine. In agreement, protection against the heterologous serotype 9 strain was low in both groups. Thus, identification of an antigen protecting against these two important
S. suis
pathotypes remains an important goal of future studies.
Publisher
American Society for Microbiology
Subject
Microbiology (medical),Clinical Biochemistry,Immunology,Immunology and Allergy
Reference26 articles.
1. Baltimore, R. S., D. L. Kasper, C. J. Baker, and D. K. Goroff. 1977. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J. Immunol.118:673-678.
2. Identification of a Novel Virulence Determinant with Serum Opacification Activity in
Streptococcus suis
3. Beineke, A., K. Bennecke, C. Neis, C. Schröder, K.-H. Waldmann, W. Baumgärtner, P. Valentin-Weigand, and C. G. Baums. 2008. Comparative evaluation of virulence and pathology of Streptococcus suis serotypes 2 and 9 in experimentally infected growers. Vet. Microbiol.128:423-430.
4. Benga, L., R. Goethe, E. Große Beilage, and P. Valentin-Weigand. 2004. Immunogenicity of murein-associated proteins from temperature-stressed Streptococcus suis cultures. J. Vet. Med. B51:272-277.
5. Chabot-Roy, G., P. Willson, M. Segura, S. Lacouture, and M. Gottschalk. 2006. Phagocytosis and killing of Streptococcus suis by porcine neutrophils. Microbiol. Path.41:21-32.
Cited by
89 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献